Park National Corp OH Has $10.93 Million Stock Position in Medtronic PLC $MDT

13 Sep 2025, 12:46 by Jessica Moore · The Cerbat Gem

Park National Corp OH lowered its stake in Medtronic PLC (NYSE:MDT – Free Report) by 1.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,374 shares of the medical technology company’s stock after selling 1,408 shares during the period. Park National Corp OH’s holdings in Medtronic were worth $10,929,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Harbor Investment Advisory LLC raised its stake in shares of Medtronic by 2.8% during the second quarter. Harbor Investment Advisory LLC now owns 11,485 shares of the medical technology company’s stock valued at $1,001,000 after acquiring an additional 312 shares during the last quarter. Kera Capital Partners Inc. bought a new position in shares of Medtronic during the second quarter valued at $298,000. Rowlandmiller & PARTNERS.ADV raised its stake in shares of Medtronic by 8.1% during the second quarter. Rowlandmiller & PARTNERS.ADV now owns 17,121 shares of the medical technology company’s stock valued at $1,492,000 after acquiring an additional 1,285 shares during the last quarter. Cullen Investment Group LTD. raised its stake in shares of Medtronic by 7.2% during the second quarter. Cullen Investment Group LTD. now owns 85,921 shares of the medical technology company’s stock valued at $7,490,000 after acquiring an additional 5,802 shares during the last quarter. Finally, Swedbank AB raised its stake in shares of Medtronic by 2.5% during the first quarter. Swedbank AB now owns 594,806 shares of the medical technology company’s stock valued at $53,449,000 after acquiring an additional 14,385 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $94.05 on Friday. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $96.25. The firm has a fifty day simple moving average of $91.50 and a 200 day simple moving average of $88.28. The company has a market capitalization of $120.64 billion, a PE ratio of 25.91, a P/E/G ratio of 2.48 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter last year, the firm earned $1.23 earnings per share. Medtronic’s quarterly revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 17th. Shareholders of record on Friday, September 26th will be issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is presently 78.24%.

Wall Street Analyst Weigh In

MDT has been the subject of several analyst reports. Wolfe Research raised shares of Medtronic from an “underperform” rating to a “peer perform” rating in a research note on Monday, June 30th. Morgan Stanley reaffirmed an “overweight” rating and set a $107.00 price target (up previously from $98.00) on shares of Medtronic in a research note on Tuesday, July 15th. UBS Group raised their price target on shares of Medtronic from $94.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 20th. Mizuho raised their price target on shares of Medtronic from $98.00 to $100.00 and gave the company an “outperform” rating in a research note on Wednesday, July 16th. Finally, Sanford C. Bernstein raised their price target on shares of Medtronic from $97.00 to $98.00 and gave the company an “outperform” rating in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.14.

Check Out Our Latest Stock Analysis on Medtronic

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the sale, the executive vice president directly owned 35,615 shares in the company, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The stock was bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.26% of the company’s stock.

About Medtronic

(Free Report)